Radius is a leading company in the discovery and development of a new generation of drug therapies for osteoporosis and women's health. The company's first drug in clinical trials is designed to build new bone in patients with osteoporosis, with the goal of reducing the risk of future fractures and improving the quality of life. Their long-term focus is on additional areas in women's health that include symptoms of menopause, reproductive disorders, and frailty associated with aging. Radius's scientific leadership includes some of the world's leading researchers in the fields of bone metabolism, endocrinology, and medicinal chemistry, and the company has a broad foundation in nuclear hormone receptors.
Radius Health startet mit Analysten-Support im Rücken Breakout auf 52 Wochenhoch Die Aktie wurde gerade eben von der Citigroup von Neutral auf Kaufen hochgestuft und das Kursziel von 24 USD auf 40 USD angepasst. Der Impuls durch die Hochstufung wird durch die signifikante Anhebung des Kursziels deutlich hervorgehoben. Zur Begründung hieß es: Der genaue Blick des Analysten auf die klinische...
STOCKHOLM, SVERIGE, 13 June 2024 - SciBase Holding AB ("SciBase") [STO: SCIB], SciBase, a leading developer of AI-based solutions for skin diseases, today announces the election...
Radius Health stock maintains Sector Weight rating by KeyBanc
Seaport bearish on Radius Health shares amid scrap market pressures
